ADA 2022 Wrap Up: Iterative Progress On Glucose Control, No Big Surprises
Executive Summary
The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.
You may also be interested in...
Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data
Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.
Dexcom Kiboshes Insulet Merger Rumors
Bloomberg reported on 23 May that Dexcom is considering acquiring Insulet to become a diabetes tech giant. Dexcom said on 31 May that it is not in “active discussions” about a merger with anyone right now.
FDA Clears Abbott’s Libre 3
Abbott’s FreeStyle Libre 3 system will soon be available in the US. It is 70% smaller than the Libre 2 while also providing better accuracy.